TCGA-AN-A0XN-01A-21R-A109-07
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
- overall_survival_months
- 0
- os_event
- false
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.690
- HEDGEHOG_SIGNALING+0.490
- INFLAMMATORY_RESPONSE+0.490
- ANGIOGENESIS+0.480
- TGF_BETA_SIGNALING+0.480
- TNFA_SIGNALING_VIA_NFKB+0.460
- UV_RESPONSE_DN+0.460
- HYPOXIA+0.450
- KRAS_SIGNALING_UP+0.410
- COAGULATION+0.380
Top 10 suppressed
- DNA_REPAIR-0.400
- E2F_TARGETS-0.360
- OXIDATIVE_PHOSPHORYLATION-0.340
- MYC_TARGETS_V1-0.290
- MYC_TARGETS_V2-0.280
- PEROXISOME-0.270
- G2M_CHECKPOINT-0.250
- FATTY_ACID_METABOLISM-0.210
- BILE_ACID_METABOLISM-0.180
- ADIPOGENESIS-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-E9-A1NG-01A-21R-A14M-07 | — | A | 0.934 |
| 2 | SRR26320074 | — | — | 0.913 |
| 3 | TCGA-43-6647-01A-11R-1820-07 | — | cohortSQ1 | 0.911 |
| 4 | TCGA-CR-6474-01A-11R-1873-07 | — | — | 0.896 |
| 5 | TCGA-DK-A1AF-01A-11R-A13Y-07 | — | — | 0.890 |
| 6 | TCGA-46-3767-01A-01R-0980-07 | — | cohortSQ1 | 0.881 |
| 7 | SRR15069613 | — | — | 0.880 |
| 8 | X17a4d870.71ef.4580.91db.071219517f26 | — | cohortSQ1 | 0.876 |
| 9 | SRR23303737 | — | — | 0.872 |
| 10 | TCGA-64-5815-01A-01R-1628-07 | — | cohortA1 | 0.871 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.690 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.490 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.490 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.480 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.480 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.460 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.460 | Inavolisib | — uncovered |
| HYPOXIA | 0.450 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.410 | Inavolisib | — uncovered |
| COAGULATION | 0.380 | Binimetinib | — uncovered |
| COMPLEMENT | 0.370 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.360 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.360 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.350 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.330 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.320 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.310 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.270 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.270 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.250 | Idelalisib | — uncovered |